DiscoverBack Bay Life Science ReportThe Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates
The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates

The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates

Update: 2023-08-29
Share

Description

In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.” This conversation explores the dynamics and data within the emerging ADC field, including:

  • Background information on the class of therapeutics known as ADCs, which have been on the market since 2000
  • The number of headlines around ADCs lately, especially the standing ovation the data from Enhertu received at ASCO in 2022, making waves in breast cancer treatment
  • Deal structures and the BD side of ADCs, and their extended revenue generation potential
  • Where the field is headed, in terms of clinical, BD and commercial standpoints

Read and connect with our authors:  The Transactional Landscape Of ADCs: A Payday for Payloads

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates

The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates

Peter Bak, PhD